All In Biotech

Drug Trial Radar · NCT01792713

Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

Randomisierte, Doppelblinde, Plazebo-kontrollierte Prüfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Verträglichkeit Einer 2%Igen Sertaconazol-Crème Bei Patienten Mit Atopischer Dermatitis (Abridged)

Last checked: Nov 20, 2026Latest source record: May 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Feb 2013

Primary completion

Sep 2013

Study completion Feb 2014

Sponsor

Lead sponsor
Spirig Pharma Ltd.Industry
Sponsor type
Industry
First posted
Feb 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis

Conditions

  • Skin Alterations Associated With Atopic Dermatitis

Interventions

  • Sertaconazole 2% creamDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Patient Global Assessment (PGA)Time frame: day 1, day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsmedizin Charité Berlin, Abteilung für Dermatologie und Allergologie

    Berlin, Germany

  • Universitätsklinikum Münster, Klinik für Hautkrankheiten

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.